Please assess the completion status of the following clinical trial:

Trial Title: Co-trimoxazole as Maintenance Therapy for Melioidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 15 years~2. Culture-confirmed melioidosis~3. Currently on oral co-trimoxazole for 12(+2) weeks without any clinical evidence of active melioidosis~4. High likelihood of completing at least 6 months follow up~5. Willingness to participate in the study and written, informed consent obtained from the patient~Exclusion Criteria:~1. Pregnancy or breast feeding~2. Contraindications to TMP-SMX: G6PD, severe adverse reactions grade 3-4 occurring during first 12 weeks of treatment~3. Relapse melioidosis with at least 2 year symptom free period from last episode

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Co-trimoxazole 12 (Type: ACTIVE_COMPARATOR): Receive treatment with co-trimoxazole for 12 weeks.
- Co-trimoxazole 20 (Type: EXPERIMENTAL): Receive treatment with co-trimoxazole for 20 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).